PLA2G4D

Across TCGA pan-cancer cohorts, PLA2G4D Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLA2G4D data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLA2G4D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLA2G4D expression acts as an unfavorable survival marker.

UCEC, STAD, and CHOL are the cancer types where PLA2G4D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
STAD	DFS	Median	All	0.127	0.492	.032	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	OS	Median	III,IV	0.197	0.684	.013	3	view →
COAD	OS	Median	IV	0.140	0.657	.035	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLA2G4D–UCEC (OS)

Open the UCEC breakdown →